Prospect of a dopamine contribution in the next generation of antidepressant drugs: The triple reuptake inhibitors

Current Drug Targets

Volumn 10, Issue 11, 2009, Pages 1069-1084

  Guiard, Bruno P ^a,b   El Mansari, Mostafa ^a   Blier, Pierre ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Antidepressant; Dopamine; Monoamine transporters; Mood disorders; Neurogenesis; Triple reuptake inhibitors

Indexed keywords

1 (3,4 DICHLOROPHENYL) 3 AZABICYCLO[3.1.0]HEXANE; 1 CYCLOHEXYL 3 DIMETHYLAMINO 2 (2 NAPHTHYL) 1 PROPANOL; 1 [1 (4 CHLOROPHENYL)CYCLOBUTYL] 3 METHYLBUTANAMINE; 3 METHYLAMINO 2 (2 NAPHTHYL) 1 PHENYL 1 PROPANOL; 6 (4 ETHYNYLPHENYL) 1,2,3,5,6,10B HEXAHYDROPYRROLO[2,1 A]ISOQUINOLINE; ALPHA 1 ADRENERGIC RECEPTOR; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; ESCITALOPRAM; HALOPERIDOL; IDAZOXAN; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; NOMIFENSINE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; PRC 200 SS; REBOXETINE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRIPLE REUPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANOXERINE; NEUROTRANSMITTER UPTAKE INHIBITOR;

ADRENERGIC STIMULATION; BINDING AFFINITY; CLINICAL TRIAL; DENTATE GYRUS; DEPRESSION; DIARRHEA; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG BINDING; DRUG CLASSIFICATION; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ELECTROPHYSIOLOGY; EXPERIMENTAL MODEL; FORCED SWIMMING TEST; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; IMMOBILIZATION; INNERVATION; LOCUS CERULEUS; MAJOR DEPRESSION; MESOLIMBIC DOPAMINERGIC SYSTEM; NAUSEA; NERVE CELL STIMULATION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; NORADRENALIN RELEASE; NORADRENERGIC SYSTEM; REVIEW; SEROTONINERGIC NERVE; SEROTONINERGIC SYSTEM; SUBVENTRICULAR ZONE; TAIL SUSPENSION TEST; UNSPECIFIED SIDE EFFECT; VOMITING; METABOLISM; PHYSIOLOGY;

ANTIDEPRESSIVE AGENTS; DEPRESSION; DOPAMINE; HUMANS; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; SEROTONIN;

EID: 70450203499     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009789735156     Document Type: Review

References (203)

1. Slattery DA, Hudson AL, Nutt, DJ. Invited review: the evolution of antidepressant mechanisms. Fundam Clin Pharmacol 2004; 18: 1-21.
2. Morilak DA and Frazer A. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol 2004; 7: 193-218. (Pubitemid 38823288)
3. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid d epletion of plasma tryptophan. Arch Gen Psychiat 1990; 47: 411-418
4. Leonard BE. Psychopathology of depression. Drugs Today 2007; 43: 705-716
5. Ruhé HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a metaanalysis of monoamine depletion studies. Mol Psychiatry 2007; 12: 331-359
6. Stockmeier CA. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J Psychiatry Res 2003; 37: 357-373
7. Arborelius L, Nomikos GG, Hertel P, Salmi P, Grillner P, Hook B B, et al. The 5-HT1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram. Naunyn-Schmied Arch Pharmacol 1996; 353: 630-640 (Pubitemid 126425785)
8. Malagie I, Trillat AC, Douvier E, Anmella MC, Dessalles MC, Jacquot C, et al. Regional differences in the effect of the combined treatment of WAY 100635 and fluoxetine: an in vivo microdialysis study. Naunyn-Schmied Arch Pharmacol 1996; 354:785-790
9. Hjorth S, Auerbach SB. Lack of 5-HT1A autoreceptor desensitization following chronic citalopram treatment, as determined by in vivo microdialysis. Neuropharmacology 1994; 33: 331-334
10. Bosker FJ, Cremers TI, Jongsma ME, Westerink BH, Wikstrom HV, den Boer JA. Acute and chronic effects of citalopram on postsynaptic 5- hydroxytryptamine(1A) receptor-mediated feedback: a microdialysis study in the amygdala. J Neurochem 2001; 76: 1645-1653
11. Moret C and Briley M. Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain. Eur J Pharmacol 1996; 295: 189-197 (Pubitemid 26027137)
12. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7: 137-151 (Pubitemid 43151600)
13. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 2003; 13: 57-66. (Pubitemid 36313278)
14. Mazeh D, Shahal B, Aviv A, Zemishlani H, Barak Y. A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. Int Clin Psychopharmacol 2007; 22: 371-375 (Pubitemid 47530842)
15. Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007; 22: 323-329 (Pubitemid 47530836)
16. Shelton RC. The dual-action hypothesis: does pharmacology matter? J Clin Psychiatry 2004; 65 (Suppl. 17): 5-10.
17. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001; 62: 869-877 (Pubitemid 33131173)
18. Guelfi JD, White C, Hackett D, Guichoux JY, Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995; 56: 450-458
19. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiat 2001; 178: 234-241
20. Lenox-Smith AJ, Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol 2008; 23: 113-119
21. Thase ME. Are SNRIs more effective than SSRIs? a review of the current state of the controversy. Psychopharmacol Bull 2008; 41: 58-85.
22. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006; 31: 122-131
23. Chen Z, Skolnick P. Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opin Invest Drugs 2007; 16: 1365-1377 (Pubitemid 47491407)
24. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiat 2007; 64: 327-337
25. Waldinger MD, van De Plas A, Pattij T, van Oorschot R, Coolen LM, et al. The selective serotonin re-uptake inhibitors fluvoxamine and paroxetine differ in sexual inhibitory effects after chronic treatment. Psychopharmacology (Berl) 2002; 160: 283-289 (Pubitemid 34230680)
26. Mos J, Mollet I, Tolboom JT, Waldinger MD, Olivier B. A comparison of the effects of different serotonin reuptake blockers on sexual behaviour of the male rat. Eur Neuropsychopharmacol 1999; 9: 123-135 (Pubitemid 29073693)
27. Fava M, Rankin M. Sexual functioning and SSRIs. J Clin Psychiatry 2002; 63 (Suppl. 5): 13-16
28. Breuer ME, Chan JS, Oosting RS, Groenink L, Korte SM, Campbell U, et al. The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects. Eur Neuropsychopharmacol 2008; 18: 908-916
29. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001; 7: 541-547
30. Rantamaki T, Castren E. Targeting TrkB neurotrophin receptor to treat depression. Expert Opin Ther Targets 2008; 12: 705-715 (Pubitemid 351877299)
31. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiat 1997; 54: 597-606.
32. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539-7547
33. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 2003; 54: 363-375 (Pubitemid 37267863)
34. Naranjo CA, Tremblay LK, Busto UE. The role of the brain reward system in depression. Prog Neuropsychopharmacol. Biol Psychiatry 2001; 25: 781-823.
35. D'Aquila PS, Collu M, Gessa GL, Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000; 405: 365-373 (Pubitemid 30734193)
36. Hasler G, Fromm S, Carlson PJ, Luckenbaugh DA, Waldeck T, Geraci M, et al. Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiat 2008; 65: 521-531 (Pubitemid 351645048)
37. McLean A, Rubinsztein JS, Robbins TW, Sahakian BJ. The effects of tyrosine depletion in normal healthy volunteers: implications for unipolar depression. Psychopharmacology (Berl) 2004; 171: 286-297 (Pubitemid 38200067)
38. Kapur S, Mann JJ. Role of the dopaminergic system in depression. Biol Psychiatry 1992; 32: 1-17.
39. Jimerson DC. Neurotransmitter hypotheses of depression. Research update. Psychiatr. Clin North Am 1984; 7: 563-573
40. Mitani H, Shirayama Y, Yamada T, Kawahara R. Plasma levels of homovanillic acid, 5-hydroxyindoleacetic acid and cortisol, and serotonin turnover in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 531-534
41. Papakostas GI. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol 2006; 16: 391-402.
42. Engstrom G, Alling C, Blennow K, Regnell G, Traskman-Bendz L. Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters. Monoamine metabolites in 120 suicide attempters and 47 controls. Eur Neuropsychopharmacol 1999; 9: 399-405.
43. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997; 12 (Suppl. 3): S7-14. (Pubitemid 27414585)
44. Hamner MB, Diamond BI. Plasma dopamine and norepinephrine correlations with psychomotor retardation, anxiety, and depression in non-psychotic depressed patients: a pilot study. Psychiatry Res 1996; 64: 209-211
45. Roy A, Karoum F, Pollack S. Marked reduction in indexes of dopamine metabolism among patients with depression who attempt suicide. Arch Gen Psychiat 1992; 49: 447-450
46. Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway GA. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiatry 2002; 52: 740-748
47. Shah PJ, Ogilvie AD, Goodwin GM, Ebmeier KP. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol Med 1997; 27: 1247-1256 (Pubitemid 27494090)
48. D'Haenen HA, Bossuyt A. Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry 1994; 35: 128-132 (Pubitemid 2045648)
49. Meyer JH, Kruger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A, et al. Lower dopamine transporter binding potential in striatum during depression. Neuroreport 2001; 12: 4121-4125 (Pubitemid 33152464)
50. Smolders I, Clinckers R, Meurs A, De Bundel D, Portelli J, Ebinger G, et al. Direct enhancement of hippocampal dopamine or serotonin levels as a pharmacodynamic measure of combined antidepressant- anticonvulsant action. Neuropharmacology 2008; 54: 1017-1028
51. Kitamura Y, Kitagawa K, Kimoto S, Sagara H, Shibata K, Kawasaki H, et al. Selegilin exerts antidepressant-like effects during the forced swim test in adrenocorticotropic hormone-treated rats. J Pharmacol Sci 2008; 106: 639-644 (Pubitemid 351556243)
52. Dhir A, Kulkarni SK. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Eur J Pharmacol 2007; 568: 177-185 (Pubitemid 46976903)
53. Yamada J, Sugimoto Y, Yamada S. Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test. Eur J Pharmacol 2004; 504: 207-211 (Pubitemid 39488216)
54. Zocchi A, Varnier G, Arban R, Griffante C, Zanetti L, Bettelini L, et al. Effects of antidepressant drugs and GR 205171, an neurokinin- 1 (NK1) receptor antagonist, on the response in the forced swim test and on monoamine extracellular levels in the frontal cortex of the mouse. Neurosci Lett 2003; 345: 73-76 (Pubitemid 36734865)
55. Cooper BR, Hester TJ, Maxwell RA. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther 1980; 215: 127-134
56. Basso AM, Gallagher KB, Bratcher NA, Brioni JD, Moreland RB, Hsieh GC, et al. Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test. Neuropsychopharmacology 2005; 30: 1257-1268
57. Cryan JF, Page ME, Lucki I. Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology (Berl) 2005; 182: 335-344 (Pubitemid 41464645)
58. Shimazu S, Minami A, Kusumoto H, Yoneda F. Antidepressantlike effects of selegiline in the forced swim test. Eur Neuropsychopharmacol 2005; 15: 563-571 (Pubitemid 41219628)
59. Tejani-Butt S, Kluczynski J, Pare WP. Strain-dependent modification of behavior following antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 7-14. (Pubitemid 36126641)
60. Birkmayer W, Riederer P, Linauer W, Knoll J. L-deprenyl plus Lphenylalanine in the treatment of depression. J Neural Transm1984; 59: 81-87
61. Mann JJ, Friedman E, Georgotas A, Gershon S. The antidepressant effects of trazodone and inhibition of platelet serotonin reuptake. Commun Psychopharmacol 1980; 4: 293-301. (Pubitemid 11095430)
62. Prica C, Hascoet M, Bourin M. Behav. Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression? Brain Res 2008; 194: 92-99
63. Reneric JP, Lucki I. Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology (Berl) 1998; 136: 190-197 (Pubitemid 28137959)
64. Zisook S, Rush AJ, Haight BR, Clines DC, Rockett CB. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry 2006; 59: 203-210 (Pubitemid 43208965)
65. Nelson JC. Treatment of antidepressant nonresponders: augmentation or switch? J Clin Psychiatry 1998; 59 (Suppl. 15): 35-41.
66. Bodkin JA, Lasser RA, Wines JD, Gardner DM, Baldessarini RJ. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997; 58: 137-145
67. Brocco M, Dekeyne A, Papp M, Millan MJ. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behav Pharmacol 2006; 17: 559-572 (Pubitemid 44526732)
68. Lattanzi L, Dell'Osso L, Cassano P, Pini S, Rucci P, Houck PR, et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002; 4: 307-314
69. Corrigan FM, Davidson A, Heard H. The role of dysregulated amygdalic emotion in borderline personality disorder. Med Hypotheses 2000; 54: 574-579 (Pubitemid 30311546)
70. Izumi T, Inoue T, Kitagawa N, Nishi N, Shimanaka S, Takahashi Y, et al. Open pergolide treatment of tricyclic and heterocyclic antidepressant- resistant depression. J Affect Disord 2000; 61: 127-132
71. Goldberg JF, Frye MA, Dunn RT. Pramipexole in refractory bipolar depression. Am J Psychiat 1999; 156: 798.
72. Muscat R, Papp M, Willner P. Antidepressant-like effects of dopamine agonists in an animal model of depression. Biol Psychiatry 1992; 31: 937-946
73. Cassano P, Lattanzi L, Soldani F, Navari S, Battistini G, Gemignani A, et al. Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety 2004; 20: 131-138 (Pubitemid 39587564)
74. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiat 2004; 161: 564-566
75. Zarate CA, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, et al. Pramipexole for bipolar II depression: a placebo- controlled proof of concept study. Biol Psychiatry 2004; 56: 54-60. (Pubitemid 38813406)
76. Fava M. Augmentation and combination strategies in treatmentresistant depression. J Clin Psychiatry 2001; 62 (Suppl. 18): 4-11. (Pubitemid 33736199)
77. Perugi G, Toni C, Ruffolo G, Frare F, Akiskal H. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 2001; 34: 137-141 (Pubitemid 32701763)
78. Sporn J, Ghaemi SN, Sambur MR, Rankin MA, Recht J, Sachs GS, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 2000; 12: 137-140 (Pubitemid 30672894)
79. Inoue T, Tsuchiya K, Miura J, Sakakibara S, Denda K, Kasahara T, et al. Bromocriptine treatment of tricyclic and heterocyclic antidepressant- resistant depression. Biol Psychiatry 1996; 40: 151-153 (Pubitemid 26202447)
80. Willner P, Hale AS, Argyropoulos S. Dopaminergic mechanism of antidepressant action in depressed patients. J Affect Disord 2005; 86: 37-45. (Pubitemid 40487958)
81. Dailly E, Chenu F, Renard CE, Bourin M. Dopamine, depression and antidepressants. Fundam. Clin Pharmacol 2004; 18: 601-607
82. Chenu F, Dailly E, Bourin M. Effect of antidepressant drugs on 6- OHDA-treated mice in the FST. Eur Neuropsychopharmacol 2007; 17: 187-193 (Pubitemid 44779192)
83. Lammers CH, Diaz J, Schwartz JC, Sokoloff P. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry 2000; 5: 378-388 (Pubitemid 30455951)
84. Klimke A, Larisch R, Janz A, Vosberg H, Muller-Gartner HW, Gaebel W. Dopamine D2 receptor binding before and after treatment of major depression measured by 123I.IBZM SPECT. Psychiatry Res 1999; 90: 91-101. (Pubitemid 29256139)
85. Ainsworth K, Smith SE, Zetterstrom TS, Pei Q, Franklin M, Sharp T. Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology (Berl) 1998; 140: 470-477 (Pubitemid 28566846)
86. Pogarell O, Koch W, Popperl G, Tatsch K, Jakob F, Zwanzger P, Mulert C, et al. Striatal dopamine release after prefrontal repetitive transcranial magnetic stimulation in major depression: preliminary results of a dynamic 123I. IBZM SPECT study. J Psychiatry Res 2006; 40: 307-314 (Pubitemid 43668986)
87. Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 2003; 28: 413-420
88. Skolnick P, Krieter P, Tizzano J, Basile A, Popik P, Czobor P, et al. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor. CNS Drug Rev 2006; 12: 123-134
89. Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS. "Broad spectrum" antidepressants: is more better for the treatment of depression? Life Sci 2003; 73: 3175-3179
90. Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006; 5: 25-43. (Pubitemid 43796626)
91. Leggio GM, Micale V, Drago F. Increased sensitivity to antidepressants of D3 dopamine receptor-deficient mice in the forced swim test (FST). Eur Neuropsychopharmacol 2008; 18: 271-277 (Pubitemid 351232176)
92. Di Giovanni G, Di Matteo V, Esposito E. Serotonin-dopamine interaction: electrophysiological evidence. Prog Brain Res 2008; 172: 45-71.
93. Adell A, Celada P, Abellan MT, Artigas F. Origin and functional role of the extracellular serotonin in the midbrain raphe nuclei. Brain Res Rev 2002; 39:154-180 (Pubitemid 35341097)
94. Kalen P, Skagerberg G, Lindvall O. Projections from the ventral tegmental area and mesencephalic raphe to the dorsal raphe nucleus in the rat. Evidence for a minor dopaminergic component. Exp Brain Res 1988; 73: 69-77.
95. Mansour A, Meador-Woodruff JH, Bunzow JR, Civelli O, Akil H, Watson SJ. Localization of dopamine D2 receptor mRNA and D1 and D2 receptor binding in the rat brain and pituitary: an in situ hybridization-receptor autoradiographic analysis. J Neurosci 1990; 10: 2587-2600
96. Suzuki M, Hurd YL, Sokoloff P, Schwartz JC, Sedvall G. D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res 1998; 779: 58-74. (Pubitemid 28039940)
97. Guiard BP, El Mansari M, Merali Z, Blier P. Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol 2008; 11: 625-639 (Pubitemid 351931823)
98. Dong J, Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl) 2001; 155: 52-57 (Pubitemid 32295769)
99. El Mansari M, Ghanbari R, Janssen S, Blier P. Sustained administration of bupropion alters the neuronal activity of serotonin, norepinephrine but not dopamine neurons in the rat brain. Neuropharmacology 2008; 55: 1191-1198
100. Ghanbari R, El Mansari M, Blier P. Electrophysiological effects of the co-administration of escitalopram and bupropion on rat serotonin and norepinephrine neurons. J Psychopharmacol 2008; doi:10.1177/0269881108095714.
101. Katz N, Guiard BP, El Mansari M, Blier P. J Psychopharmacol 2009 (in press).
102. Martin-Ruiz R, Ugedo L, Honrubia MA, Mengod G, Artigas F. Control of serotonergic neurons in rat brain by dopaminergic receptors outside the dorsal raphe nucleus. J Neurochem 2001; 77: 762-775 (Pubitemid 32466773)
103. Ferre S, Artigas F. Dopamine D2 receptor-mediated regulation of serotonin extracellular concentration in the dorsal raphe nucleus of freely moving rats. J Neurochem 1993; 61: 772-775 (Pubitemid 23215828)
104. Ferre S, Cortes R, Artigas F. Dopaminergic regulation of the serotonergic raphe-striatal pathway: microdialysis studies in freely moving rats. J Neurosci 1994; 14: 4839-4846 (Pubitemid 24237906)
105. Chernoloz O, El Mansari M, Blier P. Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology 2009; 34: 651-661
106. Aman TK, Shen RY, Haj-Dahmane S. D2-like dopamine receptors depolarize dorsal raphe serotonin neurons through the activation of nonselective cationic conductance. J Pharmacol Exp Ther 2007; 320: 376-385 (Pubitemid 46025752)
107. Haj-Dahmane S. D2-like dopamine receptor activation excites rat dorsal raphe 5-HT neurons in vitro. Eur J Neurosci 2001; 14: 125-134
108. Ornstein K, Milon H, McRae-Degueurce A, Alvarez C, Berger B, Wurzner HP. Biochemical and radioautographic evidence for dopaminergic afferents of the locus coeruleus originating in the ventral tegmental area. J Neural Transm 1987; 70: 183-191 (Pubitemid 18022471)
109. Swanson LW. The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res Bull 1982; 9: 321-353
110. Yokoyama C, Okamura H, Nakajima T, Taguchi J, Ibata Y. Autoradiographic distribution of 3H.YM-09151-2, a high-affinity and selective antagonist ligand for the dopamine D2 receptor group, in the rat brain and spinal cord. J Comp Neurol 1994; 344: 121-136 (Pubitemid 2088510)
111. Guiard BP, El Mansari M, Blier P. Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus ceruleus, and dorsal hippocampus. Mol Pharmacol 2008; 74: 1463-1475
112. Elam M, Clark D, Svensson TH. Electrophysiological effects of the enantiomers of 3-PPP on neurons in the locus coeruleus of the rat. Neuropharmacology 1986; 25: 1003-1008 (Pubitemid 16050461)
113. Cedarbaum JM, Aghajanian GK. Catecholamine receptors on locus coeruleus neurons: pharmacological characterization. Eur J Pharmacol 1977; 44: 375-385
114. Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 1994; 11: 133-141 (Pubitemid 24334069)
115. Nilsson LK, Schwieler L, Engberg G, Linderholm KR, Erhardt S. Activation of noradrenergic locus coeruleus neurons by clozapine and haloperidol: involvement of glutamatergic mechanisms. Int J Neuropsychopharmacol 2005; 8: 329-339 (Pubitemid 41002488)
116. Piercey MF, Smith MW, Lum-Ragan JT. Excitation of noradrenergic cell firing by 5-hydroxytryptamine1A agonists correlates with dopamine antagonist properties. J Pharmacol Exp Ther 1994; 268: 1297-1303
117. Dremencov E, El Mansari M, Blier P. Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry 2007; 61: 671-678 (Pubitemid 46328857)
118. Szabo ST, Blier P. Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons. J Pharmacol Exp Ther 2002; 302: 983-991 (Pubitemid 34920218)
119. Szabo ST, Blier P. Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. Brain Res 2001; 922: 9-20. (Pubitemid 33152840)
120. Aluisio L, Lord B, Barbier AJ, Fraser IC, Wilson SJ, Boggs J, et al. In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor. Eur J Pharmacol 2008; 587: 141-146
121. Liang Y, Shaw AM, Boules M, Briody S, Robinson J, Oliveros A, et al. Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)- 1-phenylpropan-1-ol (PRC200-SS). J Pharmacol Exp Ther 2008; 327: 573-583
122. Shaw AM, Boules M, Zhang Y, Williams K, Robinson J, Carlier PR, et al. Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050. Eur J Pharmacol 2007; 555: 30-36 (Pubitemid 46013855)
123. Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) 2002; 160: 353-361 (Pubitemid 34253277)
124. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50: 345-350
125. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340: 249-258 (Pubitemid 28022649)
126. Maryanoff BE, McComsey DF, Gardocki JF, Shank RP, Costanzo MJ, Nortey SO, Schneider CR, Setler PE. Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships. J Med Chem 1987; 30: 1433-1454
127. Carboni E, Silvagni A. Dopamine reuptake by norepinephrine neurons: exception or rule? Crit Rev Neurobiol 2004; 16: 121-128
128. Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) 2002; 160: 353-361 (Pubitemid 34253277)
129. Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 2002; 22: 389-395 (Pubitemid 34049076)
130. nd ECNP Congress).
131. Einhorn LC, Johansen PA, White FJ. Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: studies in the ventral tegmental area. J Neurosci 1988; 8: 100-112
132. White FJ and Wang RY. Electrophysiological evidence for A10 dopamine autoreceptor subsensitivity following chronic Damphetamine treatment. Brain Res 1984; 309: 283-292
133. El Mansari M, Sanchez C, Chouvet G, Renaud B, Haddjeri N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacol 2005; 30: 1269-1277
134. Kung MP, Choi SR, Hou C, Zhuang ZP, Foulon C, Kung HF. Selective binding of 2-125I.iodo-nisoxetine to norepinephrine transporters in the brain. Nucl Med Biol 2004; 31: 533-541 (Pubitemid 38803004)
135. Tejani-Butt SM, Ordway GA. Effect of age on 3H.nisoxetine binding to uptake sites for norepinephrine in the locus coeruleus of humans. Brain Res 1992; 583: 312-315
136. Fuller RW. Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 1994; 55: 163-167 (Pubitemid 24187116)
137. Kuikka JT, Tiihonen J, Bergstrom KA, Karhu J, Hartikainen P, Viinamaki H, et al. Imaging of serotonin and dopamine transporters in the living human brain. Eur J Nucl Med 1995; 22: 346-350
138. Devoto P, Flore G, Pira L, Longu G, Gessa GL. Alpha2- adrenoceptor mediated co-release of dopamine and noradrenaline from noradrenergic neurons in the cerebral cortex. J Neurochem 2004a; 88:1003-1009 (Pubitemid 38199322)
139. Devoto P, Flore G, Pira L, Longu G, Gessa GL. Mirtazapineinduced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex. Eur J Pharmacol 2004b; 487: 105-111 (Pubitemid 38368986)
140. Shoblock JR, Maisonneuve IM, Glick SD. Differential interactions of desipramine with amphetamine and methamphetamine: evidence that amphetamine releases dopamine from noradrenergic neurons in the medial prefrontal cortex. Neurochem Res 2004; 29: 1437-1442
141. Valentini V, Frau R, Di Chiara G. Noradrenaline transporter blockers raise extracellular dopamine in medial prefrontal but not parietal and occipital cortex: differences with mianserin and clozapine. J Neurochem 2004; 88: 917-927 (Pubitemid 38199313)
142. Gresch PJ, Sved AF, Zigmond MJ, Finlay JM. Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J Neurochem 1995; 65: 111-116
143. McKittrick CR, Abercrombie ED. Catecholamine mapping within nucleus accumbens: differences in basal and amphetaminestimulated efflux of norepinephrine and dopamine in shell and core. J Neurochem 2007; 100: 1247-1256
144. Carboni E, Silvagni A, Vacca C, Di Chiara G. Cumulative effect of norepinephrine and dopamine carrier blockade on extracellular dopamine increase in the nucleus accumbens shell, bed nucleus of stria terminalis and prefrontal cortex. J Neurochem 2006; 96: 473-481
145. Carboni E, Imperato A, Perezzani L, Di Chiara G. Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 1989; 28: 653-661 (Pubitemid 19081023)
146. Giros B, Wang YM, Suter S, McLeskey SB, Pifl C, Caron MG. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopaminenorepinephrine transporters. J Biol Chem 1994; 269: 15985-15988 (Pubitemid 24209280)
147. Borsini F, Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology (Berl)1988; 94: 147-160
148. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl)1985; 85: 367-370 (Pubitemid 15123115)
149. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977; 266:730-732 (Pubitemid 8073804)
150. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in
151. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 1997; 8: 523-532 (Pubitemid 27504702)
152. Detke MJ, Rickels M, Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 1995; 121: 66-72.
153. Bannwart LM, Carter DS, Cai HY, Choy JC, Jaime-Figueroa S, Iyer PS, et al. 3,3-disubstituted pyrrolidines as selective triple serotonin/ norepinephrine/dopamine reuptake inhibitors. Bioorg Med Chem Lett 2008; 18:6062-6066
154. Riddle EL, Fleckenstein AE, Hanson GR. Role of monoamine transporters in mediating psychostimulant effects. AAPS J 2005; 7: E847-51.
155. Slotkin TA, Seidler FJ. Cholinergic receptor subtypes in the olfactory bulbectomy model of depression. Brain Res Bull 2006; 68: 341-345
156. Song C, Leonard BE. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 2005; 29: 627-647 (Pubitemid 40755458)
157. Masini CV, Holmes PV, Freeman KG, Maki AC, Edwards GL. Dopamine overflow is increased in olfactory bulbectomized rats: an in vivo microdialysis study. Physiol Behav 2004; 81: 111-119
158. Van der Stelt HM, Breuer ME, Olivier B, Westenberg HG. Permanent deficits in serotonergic functioning of olfactory bulbectomized rats: an in vivo microdialysis study. Biol Psychiatry 2005; 57;1061-1067
159. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003; 160: 1516-1518 (Pubitemid 41070930)
160. Angelucci F, Brene S, Mathe AA. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 2005; 10: 345-352 (Pubitemid 40490802)
161. Castren E. Neurotrophins as mediators of drug effects on mood, addiction, and neuroprotection. Mol Neurobiol 2004; 29: 289-302. (Pubitemid 41359112)
162. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001; 50: 260-265 (Pubitemid 32778442)
163. Duman RS. Depression: a case of neuronal life and death? Biol Psychiatry 2004; 56: 140-145
164. Pezet S, Malcangio M. Brain-derived neurotrophic factor as a drug target for CNS disorders. Expert Opin Ther Targets 2004; 8: 391-399 (Pubitemid 39359646)
165. Deltheil T, Guiard BP, Guilloux JP, Nicolas L, Delomenie C, Reperant C, et al. Consequences of changes in BDNF levels on serotonin neurotransmission, 5-HT transporter expression and function: studies in adult mice hippocampus. Pharmacol Biochem Behav 2008; 90: 174-183 (Pubitemid 351795580)
166. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002; 22: 3251-3261 (Pubitemid 35379212)
167. Adachi M, Barrot M, Autry AE, Theobald D, Monteggia LM. Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol Psychiatry 2008; 63: 642-649 (Pubitemid 351329281)
168. Guiard BP, David DJ, Deltheil T, Chenu F, Le Maitre E, Renoir T, et al. Brain-derived neurotrophic factor-deficient mice exhibit a hippocampal hyperserotonergic phenotype. Int J Neuropsychopharmacol 2008; 11: 79-92.
169. Daws LC, Munn JL, Valdez MF, Frosto-Burke T, Hensler JG. Serotonin transporter function, but not expression, is dependent on brain-derived neurotrophic factor (BDNF): in vivo studies in BDNF-deficient mice. J Neurochem 2007; 101: 641-651
170. Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T, et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA 2004; 101: 10827-10832 (Pubitemid 38955827)
171. Jones BE, Halaris AE, McIlhany M, Moore RY. Ascending projections of the locus coeruleus in the rat. I. Axonal transport in central noradrenaline neurons. Brain Res 1977; 127: 1-21.
172. Moore RY, Halaris AE. Hippocampal innervation by serotonin neurons of the midbrain raphe in the rat. J Comp Neurol1975; 164: 171-183
173. Balu DT, Hoshaw BA, Malberg JE, Rosenzweig-Lipson S, Schechter LE, Lucki I. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res 2008; 1211: 37-43.
174. Larsen MH, Hay-Schmidt A, Ronn LC, Mikkelsen JD. Temporal expression of brain-derived neurotrophic factor (BDNF) mRNA in the rat hippocampus after treatment with selective and mixed monoaminergic antidepressants. Eur J Pharmacol 2008; 578: 114-122 (Pubitemid 350309578)
175. Jacobsen JP, Mork A. The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. Brain Res 2004; 1024: 183-192 (Pubitemid 39286729)
176. Russo-Neustadt AA, Alejandre H, Garcia C, Ivy AS, Chen MJ. Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. Neuropsychopharmacology 2004; 29: 2189-2199 (Pubitemid 39578909)
177. Chen H, Pandey GN, Dwivedi Y. Hippocampal cell proliferation regulation by repeated stress and antidepressants. Neuroreport 2006; 17: 863-867 (Pubitemid 43869948)
178. Malberg JE, Schechter LE. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des 2005; 11: 145-155
179. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104-9110 (Pubitemid 32042912)
180. Altieri M, Marini F, Arban R, Vitulli G, Jansson BO. Expression analysis of brain-derived neurotrophic factor (BDNF) mRNA isoforms after chronic and acute antidepressant treatment. Brain Res 2004; 1000: 148-155 (Pubitemid 38446499)
181. Dias BG, Banerjee SB, Duman RS, Vaidya VA. Differential regulation of brain derived neurotrophic factor transcripts by antidepressant treatments in the adult rat brain. Neuropharmacology 2003; 45: 553-563
182. Conti AC, Cryan JF, Dalvi A, Lucki I, Blendy JA. cAMP response element-binding protein is essential for the upregulation of brainderived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci 2002; 22: 3262-3268 (Pubitemid 35379213)
183. Miro X, Perez-Torres S, Artigas F, Puigdomenech P, Palacios JM, Mengod G. Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and chronic fluoxetine treatment. An in situ hybridization study. Neuropharmacology 2002; 43: 1148-1157
184. Larsen MH, Rosenbrock H, Sams-Dodd F, Mikkelsen JD. Eur. Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine. J Pharmacol 2007; 555: 115-121 (Pubitemid 46048797)
185. Ivy AS, Rodriguez FG, Garcia C, Chen MJ, Russo-Neustadt AA. Noradrenergic and serotonergic blockade inhibits BDNF mRNA activation following exercise and antidepressant. Pharmacol Biochem Behav 2003; 75: 81-88 (Pubitemid 36577583)
186. Scatton B, Simon H, Le Moal M, Bischoff S. Origin of dopaminergic innervation of the rat hippocampal formation. Neurosci Lett 1980; 18: 125-131 (Pubitemid 10062013)
187. Bischoff S, Scatton B, Korf J. Biochemical evidence for a transmitter role of dopamine in the rat hippocampus. Brain Res 1979; 165: 161-165 (Pubitemid 9133275)
188. Hoglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, et al. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 2004; 7: 726-735 (Pubitemid 38859057)
189. Yang P, Arnold SA, Habas A, Hetman M, Hagg T. Ciliary neurotrophic factor mediates dopamine D2 receptor-induced CNS neurogenesis in adult mice. J Neurosci 2008; 28: 2231-2241 (Pubitemid 351317623)
190. Mori M, Jefferson JJ, Hummel M, Garbe DS. CNTF: a putative link between dopamine D2 receptors and neurogenesis. J Neurosci 2008; 28: 5867-5869
191. Volkow ND. What do we know about drug addiction? Am J Psychiat 2005; 162: 1401-1402
192. Rothman RB. High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development. Life Sci 1990; 46: 17-21.
193. Stathis M, Scheffel U, Lever SZ, Boja JW, Carroll FI, Kuhar MJ. Rate of binding of various inhibitors at the dopamine transporter in vivo. Psychopharmacology (Berl) 1995; 119: 376-384
194. Taeuber K, Zapf R, Rupp W, Badian M. Pharmacodynamic comparison of the acute effects of nomifensine, amphetamine and placebo in healthy volunteers. Int J Clin Pharmacol Biopharm 1979; 17: 32-37 (Pubitemid 9109751)
195. Haddad P. Do antidepressants have any potential to cause addiction? J Psychopharmacol 1999; 13: 300-307
196. Prieto JM, Gost A, Obiols J, Caycedo N. Amineptine dependence and schizophrenia. Biol Psychiatry 1994; 36: 266-268
197. Beer B, Stark J, Krieter P, Czobor P, Beer G, Lippa A, et al. DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. J Clin Pharmacol 2004; 44: 1360-1367
198. Rascol O, Poewe W, Lees A, Aristin M, Salin L, Juhel N, et al. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch Neurol 2008; 65: 577-583 (Pubitemid 351679649)
199. Hauser RA, Salin L, Juhel N, Konyago VL. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Mov Disord 2007; 22: 359-365 (Pubitemid 46569690)
200. Basile AS, Janowsky A, Golembiowska K, Kowalska M, Tam E, Benveniste M, Popik P, et al. Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain. J Pharmacol Exp Ther 2007; 321: 1208-1225 (Pubitemid 46762716)
201. McMillen BA, Shank JE, Jordan KB, Williams HL, Basile AS. Effect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring rat. Alcohol Clin Exp Res 2007; 31: 1866-1871
202. Frackiewicz EJ, Jhee SS, Shiovitz TM, Webster J, Topham C, Dockens RC, et al. Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. Ann Pharmacother 2002; 36: 225-230 (Pubitemid 34126811)
203. Thatte U. NS-2330 (Neurosearch). Curr Opin Invest Drugs 2001; 2: 1592-1594